# NXC-201 CAR-T

Source: https://onco.cc/drugs/nxc-201-car-t/  
OnCo record `nxc-201-car-t` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

NXC-201 CAR-T is an experimental CAR-T cell therapy from Nexcella in phase 2 trials, aimed at BCMA.

## Summary

NXC-201 CAR-T (NXC-201, HBI0101) is a CAR-T cell therapy developed by Nexcella. Its target is BCMA. The sponsor states: Autologous T cells transduced ex vivo with an anti-BCMA CAR retroviral vector, provided fresh without cryopreservation. ClinicalTrials.gov describes the intervention as: NXC-201 (formerly HBI0101) CAR-T is defined as autologous T cells transduced ex-vivo with anti-BCMA CAR retroviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA. The NXC-201 CAR-T is provided fresh without cryop. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT06097832, plans to enrol 45 participants with primary completion expected 2026-12. Status reflects the highest phase registered on ClinicalTrials.gov. The published efficacy data come from the Hadassah phase 1 in relapsed or refractory multiple myeloma (NCT04720313; Haematologica 2023): overall response 75 percent and complete response 50 percent in the first 20 patients, with only grade 1 to 2 cytokine release syndrome.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-24
- Also known as: HBI0101 CAR-T
- Tags: pipeline; ctgov-ingest
- Code: NXC-201, HBI0101
- Modality: CAR-T cell therapy
- Mechanism: Autologous T cells transduced ex vivo with an anti-BCMA CAR retroviral vector, provided fresh without cryopreservation.

## Sources

- HBI0101 phase 1 (Haematologica 2023): https://doi.org/10.3324/haematol.2022.281628
- ClinicalTrials.gov NCT04720313: https://clinicaltrials.gov/study/NCT04720313
- ClinicalTrials.gov: trials of NXC-201 CAR-T: https://clinicaltrials.gov/search?intr=NXC-201
- Sponsor pipeline page: https://www.nexcella.com

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- targets: [BCMA](https://onco.cc/targets/bcma/)
- companies: [Immix Biopharma](https://onco.cc/companies/immix-biopharma/)
- trials: [HBI0101 (NXC-201) multiple myeloma phase 1](https://onco.cc/trials/nxc-201-mm/)
- key papers: [Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial (HBI0101)](https://onco.cc/key-papers/paper-nxc-201-hbi0101-asherie-haematologica-2023/)

---
JSON: https://onco.cc/api/v1/entities/nxc-201-car-t.json